Estimation of type-specific neutralizing antibody to herpes simplex virus type 2 in uterine cervical cancer patients by a new absorption method
A simple method of estimating type-specific neutralizing antibody to type 2 herpes simplex virus (HSV-2) was devised with the use of the microneutralization system. Serially diluted serum was mixed in the well with a constant amount of type 1 virus (HSV-1), and after 3 days' incubation at 37 C, the plate was irradiated with ultraviolet light. The absorbing HSV-1 consisted of culture fluid plus an extract of infected Vero cells not especially concentrated. The well then received indicator HSV-1 or HSV-2, and after being left at 37 C for 1 hr a suspension of dispersed Vero cells was dropped into the wells, following our standard neutralization procedure. Preliminary tests with rabbit antisera showed that even a low level of HSV-2 antibody was detected by this method, unless an exceptionally high titer of HSV-1 antibody originally coexisted with the HSV-2 antibody. Sera from acutely infected persons testified to the specificity of the antibody so detected. It was revealed by means of the new technique that the rate of HSV-2 antibody was significantly higher in uterine cervical cancer patients than in control women. There was no correlation between the clinical stage of cervical cancer and the presence of HSV-2 antibody.
Antibodies to Herpes simplex virus in Jewish women with cervical cancer and in healthy Jewish women of Israel
Long-term follow-up studies on herpes simplex antibodies in the course of cervical cancer. II. Antibodies to surface antigen of Herpes simplex virus infected cells
Detection of type-specific antibody to herpes simplex virus type 1 and 2 in human sera by complement-fixation tests
Transformation of human embryonic fibroblasts by photodynamically inactivated herpes simplex virus, type 2 at supra-optimal temperature
Prevalence of type-specific antibody against type 1 and type 2 herpes simplex virus in women with abnormal cervical cytology: evidence towards pre-pubertal vaccination of sero-negative female subjects
Studies on the neutralization of herpes simplex virus. IX. Variance in complement requirement among IgG and IgM from early and late sera under different sensitization conditions
Antibodies to Herpes simplex virus types 1 and 2 in patients with squamous-cell carcinoma of uterine cervix in India
Transformation of hamster embryo fibroblasts by a specific fragment of the herpes simplex virus genome
Studies on the neutralization of herpes simplex virus. X. Demonstration of complement-requiring neutralizing (CRN) and slow-reacting CRN (s-CRN) antibodies in late IgG
Application of indirect hemagglutination test to measurement of type specific antibody to herpes simplex virus in human sera
Antibodies to Herpesvirus hominis types 1 and 2 in humans. I. Patients with genital herpetic infections
Occurrence of herpes- and adenovirus antibodies in patients with carcinoma of the cervix uteri. Measurement of antibodies to herpesvirus hominis (types 1 and 2), cytomegalovirus, EB-virus, and adenovirus
Incidence of antibody to envelope antigen of herpes simplex virus type 2 among patients with cervical carcinoma and matched controls
Total recovery of infectious virus from noninfectious type 1 poliovirus-antibody complex by heating in salts
Neutralizing antibodies to herpesvirus types 1 and 2 in carcinoma of the cervix, carcinoma in situ and cervical dysplasia
Transformation of hamster embryo and human embryo cells by temperature sensitive mutants of herpes simplex virus type 2
Discrimination of antibody to herpes B virus from antibody to herpes simplex virus types 1 and 2 in human and macaque sera.
Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.